Technical Analysis for EXAS - Exact Sciences Corporation

Grade Last Price % Change Price Change
F 53.53 -1.38% -0.75
EXAS closed down 1.38 percent on Friday, February 7, 2025, on 82 percent of normal volume.
Earnings due: Feb 19
*** please verify all earnings dates ***
9 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Fell Below 20 DMA Bearish -1.38%
180 Bearish Setup Bearish Swing Setup -1.38%
Outside Day Range Expansion -1.38%
Crossed Above 20 DMA Bullish -4.03%
Inside Day Range Contraction -4.03%
20 DMA Resistance Bearish -2.23%
Gapped Up Strength -2.23%
Fell Below 20 DMA Bearish -3.10%
Gapped Down Weakness -3.10%

   Recent Intraday Alerts

Alert Time
Down 3% about 17 hours ago
Down 2 % about 18 hours ago
60 Minute Opening Range Breakdown about 18 hours ago
Bearish 180 Entry about 18 hours ago
Fell Below Previous Day's Low about 18 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Exact Sciences Corporation Description

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing diagnostic screening products for the early detection and prevention of colorectal pre-cancer and cancer. The company develops the Cologuard, a non-invasive stool-based DNA colorectal cancer screening test that is designed to detect pre-cancerous lesions or polyps, and each of the four stages of colorectal cancer. Its Cologuard test includes proprietary and patented methods that isolate and analyze the human DNA that are shed into stool every day from the exfoliation of cells that line the colon; and also protein marker to detect blood in the stool, utilizing an antibody-based fecal immunochemical test. The company's stool-based DNA colorectal cancer screening technology also focuses on the inflammatory bowel disease. It has collaboration, license, and purchase agreement with Genzyme Corporation, as well as with Mayo Clinic for developing tests to detect other gastro-intestinal cancers, primarily esophageal and pancreatic cancer. Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.


Classification

Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Medicine Cancer Medical Test Pancreatic Cancer Lab Testing Colorectal Cancer Inflammatory Bowel Disease Polyp Molecular Diagnostics Cancer Screening Genzyme Mayo Clinic

Is EXAS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Comments

Indicators

Indicator Value
52 Week High 79.62
52 Week Low 40.624
Average Volume 2,095,038
200-Day Moving Average 56.72
50-Day Moving Average 57.63
20-Day Moving Average 54.84
10-Day Moving Average 55.16
Average True Range 2.37
RSI (14) 41.52
ADX 7.3
+DI 16.83
-DI 22.53
Chandelier Exit (Long, 3 ATRs) 53.76
Chandelier Exit (Short, 3 ATRs) 56.91
Upper Bollinger Bands 58.18
Lower Bollinger Band 51.49
Percent B (%b) 0.31
BandWidth 12.21
MACD Line -0.68
MACD Signal Line -0.75
MACD Histogram 0.0618
Fundamentals Value
Market Cap 9.91 Billion
Num Shares 185 Million
EPS -1.19
Price-to-Earnings (P/E) Ratio -44.98
Price-to-Sales 3.56
Price-to-Book 2.91
PEG Ratio -1.07
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 57.20
Resistance 3 (R3) 57.24 56.06 56.59
Resistance 2 (R2) 56.06 55.13 56.04 56.39
Resistance 1 (R1) 54.80 54.55 54.20 54.75 56.18
Pivot Point 53.61 53.61 53.32 53.59 53.61
Support 1 (S1) 52.35 52.68 51.76 52.31 50.88
Support 2 (S2) 51.16 52.10 51.14 50.67
Support 3 (S3) 49.90 51.16 50.47
Support 4 (S4) 49.86